Literature DB >> 7533670

Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines.

T Bogush1, G Smirnova, I Shubina, A Syrkin, J Robert.   

Abstract

Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and cellular DNA: (1) by direct evaluation of the quenching of anthracycline fluorescence due to the intercalation of the drug into DNA and (2) by the measurement of Hoechst 33258 fluorescence associated with its displacement from DNA-binding sites for which it competes with the anthracycline. We show that the intracellular accumulation and DNA binding of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres (dox-NS) and of daunorubicin bound to polyglutamic acid are reduced by 30%-40% in comparison with those obtained for free doxorubicin (dox) and daunorubicin, respectively. The results obtained with dox or NS-dox are not modified by prior incubation with either of these compounds. The two methods yielded similar results, and we conclude that either technique is applicable to the evaluation of the interaction of carrier-bound anthracyclines with cellular DNA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533670     DOI: 10.1007/BF00686835

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).

Authors:  G Gahrton; U Tidefelt; C Paul; M Björkholm; G Grimfors; R Hast; G Juliusson; M Järnmark; A Killander; E Kimby
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

2.  Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

Authors:  B Schott; J Robert
Journal:  Biochem Pharmacol       Date:  1989-01-01       Impact factor: 5.858

3.  Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.

Authors:  S Oudard; A Thierry; T J Jorgensen; A Rahman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture.

Authors:  S Bennis; C Chapey; P Couvreur; J Robert
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

5.  [Intravital estimation of doxorubicin accumulation in various types of cell cultures].

Authors:  T A Bogush; E P Baranov; A B Kozorez; N I Tankovich
Journal:  Antibiot Khimioter       Date:  1990-11

6.  Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines.

Authors:  S Bennis; C Garcia; J Robert
Journal:  Biochem Pharmacol       Date:  1993-05-05       Impact factor: 5.858

7.  Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells.

Authors:  M Fritzer; K Barabas; V Szüts; A Berczi; T Szekeres; W P Faulk; H Goldenberg
Journal:  Int J Cancer       Date:  1992-10-21       Impact factor: 7.396

8.  Doxorubicin resistance in P388 leukemia--evidence for reduced drug influx.

Authors:  A Ramu; H B Pollard; L M Rosario
Journal:  Int J Cancer       Date:  1989-09-15       Impact factor: 7.396

9.  Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration.

Authors:  J Tarasiuk; F Frézard; A Garnier-Suillerot; L Gattegno
Journal:  Biochim Biophys Acta       Date:  1989-09-19

Review 10.  Pharmacokinetics and metabolism of anthracyclines.

Authors:  J Robert; L Gianni
Journal:  Cancer Surv       Date:  1993
View more
  3 in total

1.  Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand.

Authors:  Vishvesh M Joshi; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

2.  Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations.

Authors:  Parisa Yousefpour; Fatemeh Atyabi; Ebrahim Vashegani Farahani; Ramin Sakhtianchi; Rassoul Dinarvand
Journal:  Int J Nanomedicine       Date:  2011-07-11

3.  Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action.

Authors:  A C de Verdière; C Dubernet; F Némati; E Soma; M Appel; J Ferté; S Bernard; F Puisieux; P Couvreur
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.